US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inspire Corporate Bond ETF

23.92

-0.0200-0.08%

Post-market: 23.920.00000.00%16:04 EDT

Volume:50.14K

Turnover:1.20M

Market Cap:385.11M

PE:- -

High:23.99

Open:23.98

Low:23.89

Close:23.94

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

BRIEF-Inspire 500 ETF (Ptl) Surpasses $300 Million In Assets Under Management

Inspire 500 ETF (Ptl) Surpasses $300 Million in Assets Under Management

THOMSON REUTERS

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.92,"timestamp":1751054400000,"preClose":23.94,"halted":0,"volume":50140,"hourTrading":{"tag":"盘后","latestPrice":23.92,"preClose":23.92,"latestTime":"16:04 EDT","volume":3,"amount":71.76,"timestamp":1751054643139},"delay":0,"floatShares":16100000,"shares":16100000,"eps":0,"marketStatus":"Market Closed","change":-0.02,"latestTime":"06-27 16:00:00 EDT","open":23.9823,"high":23.99,"low":23.8851,"amount":1200092.146835,"amplitude":0.004382,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.94,"sharesOutstanding":16100000,"nav":23.9,"aum":384794608.55,"dividendRate":0.042224,"bidAskSpread":0.004268,"postHourTrading":{"tag":"盘后","latestPrice":23.92,"preClose":23.92,"latestTime":"16:04 EDT","volume":3,"amount":71.76,"timestamp":1751054643139},"volumeRatio":0.981528316364688},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":16100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.981528316364688,"shares":16100000,"dividePrice":1.01,"high":23.99,"amplitude":0.004382,"preClose":23.94,"low":23.8851,"week52Low":22.84,"pbRate":"--","week52High":25.49,"institutionHeld":0,"latestPrice":23.92,"eps":0,"divideRate":0.042224,"volume":50140,"delay":0,"ttmEps":0,"open":23.9823,"prevYearClose":23.44,"prevWeekClose":23.96,"prevMonthClose":23.74,"prevQuarterClose":23.75,"fiveDayClose":23.96,"twentyDayClose":23.73,"sixtyDayClose":23.77},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IBD\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539257011","title":"BRIEF-Inspire 500 ETF (Ptl) Surpasses $300 Million In Assets Under Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2539257011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539257011?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:02","pubTimestamp":1748520136,"startTime":"0","endTime":"0","summary":"BRIEF-Inspire 500 ETF (Ptl) Surpasses $300 Million In Assets Under ManagementMay 29 (Reuters) - INSPIRE 500 ETF (PTL) SURPASSES $300 MILLION IN ASSETS UNDER MANAGEMENTSource text: ID:nPn6zqBv6a ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA8NX2HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ISMD","RISN","PTL","GLRY","BIBL","WWJD","FDLS","IBD","BLES"],"gpt_icon":0},{"id":"2539212256","title":"Inspire 500 ETF (Ptl) Surpasses $300 Million in Assets Under Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2539212256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539212256?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:00","pubTimestamp":1748512807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA8NX2HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RISN","BIBL","PTL","FDLS","ISMD","GLRY","BLES","IBD","WWJD"],"gpt_icon":0},{"id":"2533056586","title":"TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years","url":"https://stock-news.laohu8.com/highlight/detail?id=2533056586","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533056586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:05","pubTimestamp":1746446700,"startTime":"0","endTime":"0","summary":"Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92. SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson  today announced new data from the TREMFYA  Phase 3 QUASAR long-term extension  study in adults with moderately-to-severely active ulcerative colitis . These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week  2025.Data from the QUASAR LTE studydemonstrate patients treated with TREMFYA sustained clinical and endoscopic efficacy at Week 92: a, 1. 72% of patients were in clinical remissionb with 99% of those patients remaining corticosteroid free for 8 or more weeks through Week 92.Patients treated with TREMFYA sustained clinical and endoscopic remission regardless of prior biologic and/or JAK inhibitor treatment history.\"With these findings, TREMFYA shows the powerful impact it can have in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tremfya-guselkumab-delivers-sustained-clinical-120500832.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tremfya-guselkumab-delivers-sustained-clinical-120500832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1267930813.SGD","LU1718418525.SGD","BK4504","IBD","LU0320765646.SGD","IE0002270589.USD","IE00B1BXHZ80.USD","LU1280957306.USD","SG9999002232.USD","IE00B7SZLL34.SGD","LU0345770308.USD","LU1894683264.USD","LU1778281490.HKD","LU2468319806.SGD","LU2505996681.GBP","LU1929549753.HKD","LU1935042991.SGD","LU1674673428.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU1674673691.USD","LU2505996509.AUD","LU0466842654.USD","LU1196500208.SGD","LU0792757196.USD","LU0345769631.USD","BK4581","IE00BFTCPJ56.SGD","LU0640476718.USD","BK4568","LU0345770993.USD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LU1032955483.USD","LU1894683348.USD","LU1244550221.USD","IE0009355771.USD","JNJ","LU2347655156.SGD","LU1066051811.HKD","LU0889566641.SGD","BK4116","LU2089984988.USD","LU1732800096.USD","LU1914381329.SGD","IE00B42XCP33.USD","CD","LU1244550494.USD","BK4559","BK4588"],"gpt_icon":0},{"id":"2533586580","title":"Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586580","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586580?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease . SPY001 pharmacokinetic  data up to eight months continues to support a potential best-in-class profile, including a half-life more than three times that of vedolizumab. SPY001 pharmacodynamic  data up to eight months showed that a single dose of SPY001 resulted in rapid and sustained saturation of α4β7 receptors at expected Phase 2 trough concentrations. Spyre presented results out to eight months of follow up from its SPY001 Phase 1 program.Updated results from our ongoing Phase 1 trial of SPY001, our novel half-life extended α4β7 antibody for the treatment of IBD, continues to show that SPY001 is well tolerated, has a half-life of more than three-fold compared to vedolizumab based on population PK modeling, and sustains target engagement at expected Phase 2 trough concentrations. This longer follow-up data strengthens the potential for SPY001 to demonstrate improved in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentations-120000455.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentations-120000455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4023","BK4218","PD","LU1169589451.USD","LU1169590202.USD","PK","SYRE","BK4007","BK4181","BK4139","IBD"],"gpt_icon":0}],"pageSize":4,"totalPage":33,"pageCount":1,"totalSize":131,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2025-06-26","symbol":"IBD","amount":0.0953,"announcedDate":"2025-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-26","defaultRemindTime":1750944600000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-26","currency":"USD","dateTimestamp":1750910400000,"payDate":"2025-07-01"},{"date":"2025-05-23","symbol":"IBD","amount":0.0809,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1748007000000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-28","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1747972800000,"payDate":"2025-05-28"},{"date":"2025-04-25","symbol":"IBD","amount":0.0799,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745587800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745553600000,"payDate":"2025-04-30"},{"date":"2025-03-27","symbol":"IBD","amount":0.092,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-04-01"},{"date":"2025-02-24","symbol":"IBD","amount":0.0728,"announcedDate":"2025-02-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{}}}